RESOURCES

Where research scientists come to find up to date resources on antibody discovery against challenging membrane protein targets.

Category: Uncategorized

Webinar presented by Integral Molecular and Fierce Biotech – Redefining Antibody Specificity Profiling for IND

Thursday, June 6, 2024
8 am PT, 11 am ET, 17:00 CET
Register now

Assessment of antibody off-target reactivity is a regulatory requirement for clinical development. However, conventional screening methods, such as tissue cross-reactivity studies, are often ineffective in screening newer therapeutic modalities, and their predictive value for in vivo safety and toxicity is poor. So, what are the alternatives?

Join our webinar to learn about the new, innovative cell-based protein array approach to specificity profiling. We’ll take a deep dive into the Membrane Proteome Array (MPA), a 6,000-protein array platform that tests binding of biotherapeutics across the full human membrane proteome expressed in unfixed cells.

Attendees will learn how:

  • Integral Molecular’s MPA is used to rapidly and accurately identify potential off-target binding liabilities
  • MPA data support both lead selection and IND submissions with advantages over tissue cross-reactivity studies
  • Cell protein arrays, like the MPA, are rapidly progressing towards FDA endorsement through inclusion in CAR-T development guidelines and qualification as an antibody Drug Development Tool
 Integral Molecular and Fierce webinar 2024

Register now

Webinar presented by Integral Molecular and The Antibody Society – Harnessing Divergent Species to Access Difficult and Conserved Antibody Targets

Thursday, April 25, 2024
8 am PT, 11 am ET, 17:00 CET
View the recording

To exploit highly conserved and difficult drug targets, including GPCRs and ion channels, monoclonal antibody discovery efforts are increasingly relying on the advantages offered by divergent species such as rabbits, camelids, and chickens. Divergent host species enable robust immune responses against highly conserved binding sites and yield antibodies capable of penetrating functional pockets via long HCDR3 regions. Pan-reactive molecules are often produced by divergent hosts, and these antibodies can be tested in accessible animal models, offering a faster path to clinical development.

In this webinar, Dr. Ross Chambers will analyze gaps in therapeutic antibodies that stem from the historic use of mice and examine opportunities to exploit previously inaccessible targets through discovery in alternate species. Examples of preclinical and clinical-stage antibodies raised in divergent species will be highlighted, providing an overview of their success

Antibody Society and Integral Molecular webinar

View the recording

Webinar presented by Integral Molecular and Fierce Biotech – Innovative Research Tools to Combat Biological Threats

Thursday, October 12, 2023
8 am PT, 11 am ET, 17:00 CET
View the recording

A fundamental research question continues to resonate today: How can we proactively develop countermeasures against future viral outbreaks?

Join leaders in industry and academia for this important, one-hour discussion on the latest technologies, experiences, and strategies within the study and development of therapeutics against emerging viruses, such as influenza, SARS-CoV-2, and dengue. We’ll explore:

  • The use of pseudovirus Reporter Virus Particles (RVPs) in place of live viruses
  • How to drive the safe study of new virus variants and mutations of interest
  • Why innovative research tools play a critical role in the development of vaccines and treatments for a range of biological threats
  • Real-world case studies from top industry organizations
  • And more

 

Fierce and Integral Molecular Webinar- Mobilizing Safe Research Tools for Pandemic Preparedness. Headshots of webinar speakers: Kyle Doolan, Ph.D. of Integral Molecular, Chun-Nan Chen, Ph.D. of Single Cell Technology, Inc. and James E. Crowe, Jr., M.D. of Vanderbilt University Medical Center.

View the recording

Webinar presented by Integral Molecular and Fierce Biotech – Conquering Undruggable Targets to Obtain Preclinical Antibodies

Thursday, September 14, 2023
8 am PT, 11 am ET, 17:00 CET
Watch the webinar

Despite the remarkable growth of antibody-based therapies in recent years, numerous promising targets remain untapped. Many targets have resisted conventional discovery approaches because they are highly conserved, structurally complex, or they present other technical hurdles. In this webinar, industry experts will share innovative strategies they have used to unlock challenging targets including membrane proteins.

They will discuss:

  • Key questions that scientists should ask before embarking on an antibody discovery campaign
  • How to leverage advancements in immunization—including RNA—to target native epitopes and generate diverse antibodies
  • Strategies for unlocking conserved antibody targets using approaches such as divergent host species
  • Case studies of two challenging targets, claudin 6 and GPRC5D, with a focus on key innovations that led to the discovery of preclinical candidates including CTIM-76, a pre-IND (Investigational New Drug) stage molecule being developed for oncology therapeutics

 

Fierce Life Sciences and Integral Molecular webinar speakers banner

Watch the webinar

Genetic Engineering and Integral Molecular Present – Specificity Testing of Antibody and CAR-T Cell Therapies for IND Using the Membrane Proteome Array

 

Thursday, June 22, 2023
Watch the webinar

Rigorous specificity analysis is critical for successful drug development and a safety requirement for antibody-based therapies, such as CAR-T, entering IND. Tissue cross-reactivity (TCR) studies have been traditionally used to screen for off-target binding; however, their predictive value for in vivo safety and toxicity is poor. Integral Molecular has developed the Membrane Proteome Array (MPA) platform to de-risk antibody-based therapeutics by testing specificity across the full human membrane proteome expressed in live cells. Using sensitive high-throughput flow cytometry to identify binding interactions on a protein level, this technology has emerged as the leading solution for antibody specificity profiling.

In this GEN webinar, our panelists will discuss their experiences using the MPA to rapidly identify potential off-target interactions, resulting in successful IND filings for CAR-T cell therapies where conventional approaches did not suffice. We will also describe the newest additions to this 6,000-protein cell array and the status of its consideration by the FDA as a qualified Drug Development Tool.

With a focus on specificity screening, this webinar assembles experts in antibody discovery and development and features presentations from Integral Molecular, Cabaletta Bio, and The University of Pennsylvania.

  • Understand how Integral Molecular’s MPA is used to identify potential off-target binding liabilities
  • Learn how MPA data supports IND submissions with advantages over traditional tissue cross-reactivity studies
  • Discover how the MPA was used to rapidly evaluate the specificity of novel CAR-T cell therapies for autoimmunity and cancer

 

GEN and Integral Molecular Webinar- Specificity Testing of Antibody and CAR-T Cell Therapies for IND Using the Membrane Proteome Array. Headshots of webinar speakers: Rachel Fong of Integral Molecular, Darshil Patel of Cabaletta Bio and Donald Siegel of University of Pennsylvania.

Genetic Engineering and Integral Molecular Present – Reporter Virus Tools to Combat Current Viral Threats and the Next Pandemic

 

Thursday, November 10, 2022
Watch the webinar

The COVID-19 pandemic has brought virology to the forefront of many research programs. But how do we get ahead of the next viral threat? Limited commercial labs are licensed to conduct research using BSL-3 or BSL-4 pathogens. However, reporter virus tools such as ready-to-use Reporter Virus Particles (RVPs, i.e., pseudoviruses) have enabled virus research in a BSL-2 environment, allowing testing of sera and antibodies in high-throughput, safe neutralization assays to accelerate virology research.

In this GEN webinar, of our distinguished speakers, Dr. Hayley Crawford, will discuss Integral Molecular’s broad catalog of RVPs, including influenza A and B, Marburg virus, and the latest variants of SARS-CoV-2. Moreover, she will discuss Integral Molecular’s expertise in custom RVP projects. Additionally, panelists Dr. Sheila Keating and Dr. Natalie Anosova will describe how Integral Molecular’s extensive collection of SARS-CoV-2 variant RVPs enabled them to meet the most recent FDA guidance for variant testing of vaccines and therapeutic antibodies.

Learn more about how RVPs have enabled therapeutic research during the COVID-19 pandemic and how they can enhance virology research on current and emerging viral targets.

GEN and Integral Molecular 2022 webinar

Genetic Engineering and Integral Molecular Present – Towards IND: Specificity Profiling of Antibody-Based Therapies

 

Thursday, July 14, 2022
Watch the webinar

Rigorous specificity analysis is critical for successful drug development and a safety requirement for monoclonal antibody (mAb) based therapies, such as CAR-T, entering IND. Tissue cross-reactivity (TCR) studies have been traditionally used to screen for off-target binding, however, with poor predictive value for in vivo safety and toxicity.

Integral Molecular has developed the Membrane Proteome Array (MPA) platform to de-risk mAb-based therapeutics by testing specificity across the full human membrane proteome expressed in live cells. Using sensitive high-throughput flow cytometry to identify binding interactions on a protein level, this technology has emerged as the leading solution for antibody specificity profiling.

Towards IND: Specificity Profiling of Antibody-Based Therapies SPeakers

Integral Molecular Breaks Ground on New Headquarters, Doubling in Size

uCity Square Ground Breaking New Integral Molecular SpacePHILADELPHIA—Integral Molecular, the industry leader in membrane protein solutions, announced today that it is starting construction of its new scientific and operational headquarters at One uCity Square, Philadelphia’s largest commercial lab building. This expansion doubles the capacity for the company’s MPS Antibody Discovery pipeline and partnered programs.

The new state-of-the-art facility will encompass 50,000 square feet of combined office and laboratory space, housing up to 200 employees and advanced instrumentation to enable the discovery and development of therapeutic antibodies. The company is a founding member of Philadelphia’s biotech community and recently celebrated its 20th anniversary. Integral Molecular’s current growth phase comes just a few years after its last expansion in 2019, which saw the opening of a second research facility that more than doubled its footprint within the uCity Square community.

“Integral Molecular is a long-time leader of Philadelphia’s biotech community and we are thrilled to see the company’s continued progress and expansion in our city,” said Philadelphia Mayor Jim Kenney in a statement.

“We have experienced extraordinary growth at Integral Molecular while operating under pandemic conditions and are proud of the business challenges that we have overcome,” said Benjamin Doranz, PhD, co-founder and CEO of Integral Molecular. “Despite uncertain times, we have launched technologies that have been instrumental in the fight against COVID-19 and discovered antibodies to combat intractable cancers.”

Integral Molecular’s new facility is being developed by Wexford Science & Technology and Ventas, in partnership with the University City Science Center. The buildout designed by Strada Architecture is being constructed by Turner Construction and managed by PurePM. The new space is expected to open at One uCity in December 2022.

About Integral Molecular
Integral Molecular is the industry leader in developing and applying innovative technologies that advance the discovery of therapeutics against difficult protein targets. With 20 years of experience focused on membrane proteins and antibodies, Integral Molecular’s technologies have been integrated into the drug discovery pipelines of over 400 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, autoimmune disorders, and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses.

Lonza Early Development Services and Integral Molecular to Offer Complementary Expertise to Enhance Early De-risking of Biotherapeutics

Basel, Switzerland and Philadelphia, USA, 25 April 2022 – Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, and Integral Molecular, an industry leader in discovering and characterizing antibodies against membrane proteins, announced today a strategy to offer complementary expertise to their respective customers to better assess the risks of off-target binding of biologic drug candidates.

Unwanted immunogenicity can have severe consequences for patients and jeopardize drug development programs. Therefore, de-risking therapeutics by assessing their immunogenicity potential early is not only a regulatory requirement to support First in Human studies but also an essential tool that can significantly improve a drug candidate’s chances of success further down the development and manufacturing pathway. Immunosafety risk assessments help to ensure that the target molecule has no unwanted immunogenicity, immunotoxicity, or cross-reactivity potential.

The respective expertise can benefit drug developers in the early de-risking of their drug candidates by allowing Lonza and Integral Molecular to complement each other’s offerings in the assessment of the potential for off-target binding and activation. Lonza’s Early Development Services focuses on cell-based assays to evaluate the activity of biologic therapies upon binding. Integral Molecular de-risks therapeutic molecules by detecting off-target binding liabilities using their Membrane Proteome Array platform.

Yvette Stallwood, Head of Early Development Services, Lonza, commented: “Early immunogenicity de-risking significantly increases chances of the future success of therapies as they progress through the development pathway. Lonza’s 14 years of expertise in in silico and in vitro immunogenicity and immunotoxicity assessments complements Integral Molecular’s valuable insights into off-target binding using their Membrane Proteome Array.”

Benjamin Doranz, CEO and co-founder, Integral Molecular, added: “We are pleased to offer complementary expertise to Lonza’s cell-based assay experience for preclinical safety profiling of biologics, thereby offering drug developers a more complete evaluation methodology to select the optimal candidate to move forward to IND filing.”

About the Complementary Offerings

The Lonza services will be provided under an agreement with Lonza and the Integral Molecular services will be provided under an agreement with Integral Molecular.

About Lonza Early Development Services

Lonza Early Development Services offers a comprehensive suite of in silico and in vitro early development services to assist pharmaceutical and biotech companies in de-risking and optimizing their late candidate selection and lead candidate development process. The group, based in Cambridge (UK), also provides early, phase-appropriate non-GMP protein expression via Lonza’s Light PathTM Discovery platform.

About Lonza

Lonza is a preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our unparalleled breadth of offerings enables our customers to commercialize their discoveries and innovations in the healthcare industry.

Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With approximately 16,000 full-time employees, we comprise high-performing teams and individual talent that make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 5.4 billion with a CORE EBITDA of CHF 1.7 billion in Full-Year 2021. Find out more at www.lonza.com.

Follow @Lonza on LinkedIn
Follow @LonzaGroup on Twitter

About Integral Molecular

Integral Molecularis an industry leader in developing and applying innovative technologies that advance the discovery of therapeutics against difficult protein targets. With 20 years of experience focused on membrane proteins and antibodies, Integral Molecular’s technologies have been integrated into the drug discovery pipelines of over 400 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, autoimmune disorders, and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses.

Follow Integral Molecular on LinkedIn

Follow Integral Molecular on Twitter